Takeda acquires Millennium

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=ir

By | April 10, 2008

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1127852&highlight= by Takeda Pharmaceuticals, Japan's largest pharma company, for a whopping $8.8 billion dollars. Although Millennium will become a wholly owned subsidiary, the company will continue its operations in Cambridge Massachusetts.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech